News
-
-
-
-
-
-
PRESS RELEASE
First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025
Pentixapharm presents first-in-human data on Lu177-PentixaTher for Muscle-Invasive Bladder Cancer at ASCO-GU 2025, showing potential for bladder preservation and targeted treatment -
-
-
PRESS RELEASE
EQS-Adhoc: Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million
Pentixapharm Holding AG reports a 2024 financial year loss of EUR 14 million, including risk provisions for Myelo. Find more details in the upcoming annual report -